Photoimmunotheranostics of epithelioid sarcoma by targeting CD44 or EGFR

• DOI: 10.1016/j.tranon.2024.101966
• Publication Date: 2024-04-25T05:09:34Z
• Authors: Jiefu Jin; James D. Barnett; Yelena Mironchik; John Gross; Hisataka Kobayashi; Adam Levin; Zaver M. Bhujwalla
• Keywords: Ex vivo

Epithelioid sarcoma (ES) is a rare soft tissue neoplasm with high recurrence rates. Wide surgical resection remains the only potential curative treatment. ES presents most commonly on fingers, hands and forearm, making light-based cancer cell-targeted therapies such as near-infrared photoimmunotherapy (NIR-PIT) that target-specific, but limited penetration depth, suitable for We established CD44 EGFR were overexpressed in patient samples VA-ES-BJ human cell line. NIR-PIT of cells using antibody photosensitizer conjugates, prepared by conjugating or monoclonal to IR700, confirmed both conjugates resulted death. Neither treatment NIR light alone nor without effective. CD44-IR700-PIT greater death than EGFR-IR700-PIT, consistent increased expression cells. In tumors, EGFR-IR700 exhibited higher tumor-to-normal ratio, determined vivo fluorescence imaging, anti-tumor growth effect, compared CD44-IR700. No antitumor effect conjugate was observed vivo. Our data support evaluating use EGFR-IR700-PIT management detecting eliminating margins, superficial recurrent tumors.